Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity

NCT05444153 on ClinicalTrials.gov · last registry update 2022-11-14

Withdrawn before anyone was enrolled. Its estimated completion date, 2 October 2024, has passed with no update to the record. Primary outcome, as filed: Participants acheiving glycated haemoglobin (HbA1c) less than (<) 7 percentage (%) (Yes/No). A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: WITHDRAWN
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 0
Started: 2022-10-06
Primary completion: 2024-10-02 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Participants acheiving glycated haemoglobin (HbA1c) less than (<) 7 percentage (%) (Yes/No)

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.